Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Impaired awareness of hypoglycemia (IAH) and severe hypoglycemic events (SHEs) cause substantial morbidity and mortality in patients with type 1 diabetes (T1D). Current therapies are effective in preventing SHEs in 50–80% of patients with IAH and SHEs, leaving a substantial number of patients at risk. We evaluated the effectiveness and safety of a standardized human pancreatic islet product in subjects in whom IAH and SHEs persisted despite medical treatment. RESEARCH DESIGN AND METHODS: This multicenter, single-arm, phase 3 study of the investigational product purified human pancreatic islets (PHPI) was conducted at eight centers in North America. Forty-eight adults with T1D for >5 years, absent stimulated C-peptide, and documented IAH and SHEs despite expert care were enrolled. Each received immunosuppression and one or more transplants of PHPI, manufactured on-site under good manufacturing practice conditions using a common batch record and standardized lot release criteria and test methods. The primary end point was the achievement of HbA1c <7.0% (53 mmol/mol) at day 365 and freedom from SHEs from day 28 to day 365 after the first transplant. RESULTS: The primary end point was successfully met by 87.5% of subjects at 1 year and by 71% at 2 years. The median HbA1c level was 5.6% (38 mmol/mol) at both 1 and 2 years. Hypoglycemia awareness was restored, with highly significant improvements in Clarke and HYPO scores (P > 0.0001). No study-related deaths or disabilities occurred. Five of the enrollees (10.4%) experienced bleeds requiring transfusions (corresponding to 5 of 75 procedures), and two enrollees (4.1%) had infections attributed to immunosuppression. Glomerular filtration rate decreased significantly on immunosuppression, and donor-specific antibodies developed in two patients. CONCLUSIONS: Transplanted PHPI provided glycemic control, restoration of hypoglycemia awareness, and protection from SHEs in subjects with intractable IAH and SHEs. Safety events occurred related to the infusion procedure and immunosuppression, including bleeding and decreased renal function. Islet transplantation should be considered for patients with T1D and IAH in whom other, less invasive current treatments have been ineffective in preventing SHEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Islet cell transplantation, which has been shown to reduce hypoglycemia (48) and restore glucose counter-regulation (49), should be considered for people with type 1 diabetes who experience recurrent severe hypoglycemia (50)”
From Hypoglycemia (2018) · cites this paper as [48]
In the citing paper
“For people with type 1 diabetes with level 3 hypoglycemia and hypoglycemia unawareness that persists despite medical treatment, pancreas transplant alone or human islet transplantation may be an option, but these approaches remain experimental (127,128).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [127]
In the citing paper
“Controlled trials 62,63 and followup of recipients 64,65 in major centres showed that high rates of insulin independence can be reached, and long duration of graft function is also seen; however,”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“Nevertheless, islet transplantation continues to be offered, with good outcomes, in many centres because of its effectiveness for treating hypoglycaemia and its usefulness in conjunction with kidney transplantation in people unsuitable for SPK.62”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
In the citing paper
“In addition, regulatory hurdles from the US FDA, despite pivotal trials done by the Collaborative Islet Transplant group, 62 have been a major stumbling block for the development of islet transplantation technology in the USA.”
From The future of type 1 diabetes therapy (2025) · cites this paper as [62]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., & Rajotte, R. V. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430401 · Cited by 5,237
Self-citationStandards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942 · cited 2×
“5,000 islet equivalents (IEQ)/kg for the first dose and $4,000 IEQ/kg for subsequent doses (if any), was prepared from a single pancreas (14) and was transplanted by portal vein infusion.”
MethodResultSelf-citationStandards of Medical Care in Diabetes—2008
Dora, J. M., Kramer, C. K., & Canani, L. H. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,409
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 2×
“Severe hypoglycemia is a debilitating, life-threatening complication of T1D (1,2,6,29) that, in some patients, is refractory to medical treatment (7,8,10).”
BackgroundStandards of Medical Care in Diabetes—2008
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Clarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651 · cited 1×
“Recipient Selection Inclusion criteria included the following: age 18–65 years; T1D for $5 years; absent stimulated C-peptide; IAH and/ or marked glycemic lability (19,20); and a history of SHEs in the prior 12 months despite medical care provided by an endocrinologist or diabetologist, who asserted that the candidate…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Items 601–700 of 705
Ciacio, O., Pittau, G., Cattan, P., Dürrbach, A., & Cunha, A. S. (2021) · EMC - Técnicas Quirúrgicas - Aparato Digestivo · doi:10.1016/s1282-9129(21)45085-3
Hope Injections: The Promises of Regenerative Medicine in Curing Type 1 Diabetes Mellitus.
Fanaropoulou, N. M. (2021) · EJIFCC
Possibility of adiponectin use to improve islet transplantation outcomes
Sakata, N., Yoshimatsu, G., Chinen, K., Kawakami, R., & Kodama, S. (2022) · Scientific Reports · doi:10.1038/s41598-021-04245-0
The Possibility of Adiponectin in Islet TransplantationPreprint
Sakata, N., Yoshimatsu, G., Chinen, K., Kawakami, R., & Kodama, S. (2021) · Research Square · doi:10.21203/rs.3.rs-743029/v1
Transplantation and stem cell therapy
Bilous, F. R., Donnelly, R., & DM, F. I. I. (2021) · Wiley eBooks · doi:10.1002/9781118976074.ch34
Miura, K., Kobayashi, T., Zhang, Z., Prasoon, P., Hirose, Y., Ishikawa, H., Takizawa, K., Sakata, J., Miura, S., Sasaoka, T., et al. (2022) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.10.029
Transplantation (Islet and Solid Organ)
Flatt, A. J., Drage, M. W., Callaghan, C. J., & Senior, P. A. (2022) · doi:10.1093/med/9780198870197.003.0258
Self-citationPancreas and Islet Transplantation from Cardiac Death Donors
Chen, Z., & Zhang, P. (2022) · Springer eBooks · doi:10.1007/978-981-16-0815-5_8
Pancreas and beta cell replacement: An overview
Hawthorne, W. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824011-3.00011-4
Autologous Peripheral Blood Mononuclear Cells can Lead to Pancreatic Beta Cell Regeneration
Younis, M. (2019) · Internal Medicine Open Access · doi:10.4172/2165-8048.1000305
Ciacio, O., Pittau, G., Cattan, P., Dürrbach, A., & Cunha, A. S. (2021) · EMC - Tecniche Chirurgiche Addominale · doi:10.1016/s1283-0798(21)44572-9
Anazawa, T., & Gotoh, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00039-3
La transplantation d’îlots restaure le contrôle de la glycémie dans le diabète de type 1
(2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30158-2
Type 1 diabetes: technology and transplants
FRCP, D. L. M. (2017) · Wiley eBooks · doi:10.1002/9781119052210.ch8
Friend, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.65989-5
TRASPLANTE PANCREÁTICO COMO ALTERNATIVA TERAPÉUTICA EN LA DIABETES MELLITUS DE DIFICIL CONTROL
Quirós, M. F. C., Rojas-Chaves, S., Jacobo-Elizondo, J., Andrea, B.-M., Sanabria‐Castro, A., Sandí, V. L., & Echeverri-McCandless, A. (2022) · Revista Médica de la Universidad de Costa Rica · doi:10.15517/rmucr.v16i1.50853
Strategies to improve outcome after pancreas and islet transplantation
Leemkuil, M. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.222480755
Cell Transplantation: Allogeneic and Autologous Pancreatic Islet Cell Transplantation
Anazawa, T., Ito, T., Hata, K., Masui, T., & Taura, K. (2022) · Springer eBooks · doi:10.1007/978-981-19-0063-1_70
Evolving Approaches to Type 1 Diabetes Management
Skyler, J. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_16
La sostituzione delle beta-cellule: indicazioni al trapianto di pancreas nel diabete
Giusti, M. A., Cintorino, D., Ricotta, C., Caccamo, C., Salis, P., Gruttadauria, S., & Mattina, A. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01125-1
“L’endpoint primario, l’assenza di episodi di ipoglicemia severa e il raggiungimento di un buon controllo glicemico (emoglobina glicosilata <7%), è stato raggiunto nell’87% dei pazienti, mentre l’indipendenza dall’insulina a 1 anno è stata raggiunta nel 52,1% [19].”
BackgroundPankreasinseltransplantation – State of the Art
Ludwig, B., & Lehmann, R. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00933-1
GABA Agonist Baclofen Increases Beta cell Mass and C Peptide Level in Patients with Type 1 Diabetes
Younis, M. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.2605018
Naqvi, R. A., Naqvi, A. R., & Priyadarshini, M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.12.503816
Kaviani, M., Geramizadeh, B., & Karimzadeh, S. (2022) · Minerva Endocrinology · doi:10.23736/s2724-6507.22.03889-1
The potential of cellular transplantation to harness autoimmunity and reverse clinical diabetes
Verhoeff, K. K., & Shapiro, A. M. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85389-7.00018-1
Self-citationTrasplante de islotes pancreáticos en humanos: ¿futura solución a un problema del pasado?
Espinoza, C., Tixilema, A., Fonseca, J., Morocho, A., Shiguango, N. S., Panchano, J., Chicaiza, Á., & Chicaiza, J. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7706435
Liu, Z., Pei, G., Cai, X., Zou, J., Ding, X., Sun, P., Liang, R., Zhang, B., & Wang, S. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000128
One Waiting List for Pancreas and Islet Transplantation: The Canadian Experience
Reichman, T., & Cattral, M. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_19
Secondary Complications: Pancreas Versus Islet Transplantation
Maffi, P., Catarinella, D., & Secchi, A. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_64
Allogeneic Islet Transplantation and Future
Matsumoto, S., Asari, S., Nanno, Y., & Fukumoto, T. (2024) · Biomedical engineering · doi:10.5772/intechopen.111812
Treatment and prevention of type 1 diabetes in the 21st century
Baidal, D. A., Sosenko, J. M., & Skyler, J. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00007-3
Lessons Learned from Clinical Trials of Islet Transplantation
Berney, T., Badet, L., Berishvili, E., Buron, F., Compagnon, P., Haidar, F., Morélon, E., Peloso, A., & Thaunat, O. (2023) · Springer eBooks · doi:10.1007/978-3-031-41943-0_21
Emerging Role of Nitric Oxide in Pancreas and Pancreatic Islet Transplantation
Dugbartey, G. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-48067-6_15
Primary islet graft function and its impact on the success of pancreatic islet transplantation
Chetboun, M. (2022) · theses.fr (ABES) · doi:10.70675/a68b21c7z7cbfz4c8czb594z3b088d738426
Quelle place pour la greffe d’îlots à l’ère de la boucle fermée ?
Benhamou, P. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.04.009
Pankreasın Cerrahi Hastalıkları
Çöpelci, Y., Özşay, O., Daban, U., Varman, A., Alkan, S., Sürmeli, S., Tunç, E., Yalçın, M., Dursun, A., Göztok, M., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1348
Advances Towards Regenerative Medicines for Diabetes
Bhutia, C. L., & Cyriac, K. S. (2024) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2024.v84i06.015
“1U/kg of insulin in order to avoid excess insulin requirement 6,7 .”
BackgroundShapiro, A. M. J. (2024) · Annals of Surgery · doi:10.1097/sla.0000000000006573
Self-citationEconomics of Diabetes Mellitus and Pancreas Transplantation
Gruessner, R. W. G., & Gruessner, A. C. (2024) · Mathews Journal of Diabetes & Obesity · doi:10.30654/mjdo.10019
A Cure Within for Type 1 Diabetes: Stem Cell-derived Islet Transplantation
Agarwal, D., & Naji, A. (2025) · Transplantation · doi:10.1097/tp.0000000000005337
Self-citationTeo, A. K. S., Tan, K. S. M., Koh, Y. X., Koh, A., & Teo, A. K. K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-12-824465-4.00143-5
(2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch04
Ziobro, O., Błaszczyk, K., Bulski, J. M., Maj, F. J., Sornat, K. B., Estreicher, A., Klasa, A. M., Sobaś, A. E., & Biedka, K. (2025) · Archiv Euromedica · doi:10.35630/2025/15/2.203
“These criteria include, but are not limited to, scores from scales such as the Clarke Hypoglycemia Awareness Scale ( ≥ 4) [49].”
Methylprednisolone Protects Human Pancreatic Beta Cells From Inflammation-induced Damage
Paz-Barba, M., Peters, I., de Graaf, N., Carlotti, F., & de Koning, E. J. P. (2025) · Transplantation Direct · doi:10.1097/txd.0000000000001770
“6 Unlike pancreas transplantation, the initial loss of endocrine tissue after islet transplantation is common and is believed to happen due to a combination of factors, including instant blood-mediated inflammatory response 7 and hypoxia.”
Improved conditioning for hematopoietic chimerism induces islet tolerance to cure diabetes
Ramos, S. A., Bhagchandani, P., Burgos, D. M., Gu, X., Rodríguez, R., Nourin, N., Neukam, M., Pathak, S., Shizuru, J. A., & Kim, S. K. (2026) · JCI Insight · doi:10.1172/jci.insight.194491
“Transplantation of MHC-mismatched allogeneic islets is an FDA-approved approach to reverse diabetes after pancreatic β cell loss (1, 2).”
Carr, A. L. J., Shah, R., Marfil‐Garza, B. A., Lam, A. P., Dajani, K. Z., Anderson, B. L., Owen, R. J., O’Gorman, D., Kin, T., Bigam, D. L., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0329074
“Islet transplantation (ITx) is an established treatment for select individuals with type 1 diabetes in whom severe hypoglycemia impacts quality of life and poses significant threat to overall health and prognosis [1–3].”
Self-citationMultiple Imputation for Small, Extremely High Efficacy Clinical Trials with Binary EndpointsPreprint
Tan, Y. V., Xu, G., & Wang, C. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2510.19011
deHaseth, N. H., Gonzalez, G. C., Stock, A. A., Claure, A. L., Orlando, G., Tomei, A. A., & Ziebarth, N. (2025) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-025-00878-7
“Transplanting allogeneic pancreatic islet cells isolated from cadaveric pancreata to replace the lost insulin-secreting β cells improves metabolic control and quality of life [5, 6].”
Jiang, H., Henley, D., & Jiang, F. (2025) · World Journal of Transplantation · doi:10.5500/wjt.v15.i4.101926
Kato, H., Sigdel, T. K., Sheta, M., Omori, K., Qi, M., KANDEEL, F. R., & Komatsu, H. (2025) · Cell Transplantation · doi:10.1177/09636897251390960
“Published reports and registry data further emphasize that while relatively low purity thresholds of ~30% to 50% are generally accepted for product release, achieving sufficient islet mass is operationally prioritized 9–12 .”
Ouahmi, H., Massa, F., Allart, E., Cougnon, M., Rouleau, M., OBBERGHEN, E. V., Shkreli, M., Sicard, A., & Pisani, D. F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.24.689446
Kong, L., Zhang, Y., Wang, C., & Tan, Y. V. (2026) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2026.2729801
Thakur, G., Han, J.-H., Jo, C.-H., Oh, S.-J., Kim, T.-S., Hong, C., Lee, S., Kumar, R., Kang, Y., & Rho, G. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00979
Oliveira, T. C., Forni, M. F., Santos, A. F., Wailemann, R. A. M., Terra, L. F., Andreone, L., Gomes, V. M., da Silva, J. M., Rosa-Fernandes, L., Sogayar, M. C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-951683/v1
Donor pancreas conditions that preserve therapeutic potential of human islet cell preparations
Paep, D. L. D. (2023) · VUBIR (Vrije Universiteit Brussel)
Ali, N. (2024) · Radboud Repository (Radboud University)
Boosting Beta-Cell Replacement Therapy For Treatment of Type 1 Diabetes
Monteiro Carvalho Mori Cunha, J. (2016) · Lirias (KU Leuven)
Yahaya, N. (2020) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
The anterior chamber of the eye as an islet transplantation site in type-2 diabetes
Tun, S. B. B. (2023) · Open Archive (Karolinska Institutet)
Diabetes internacional : órgano oficial de la Sociedad Interamericana de Diabetes
(n.d.) · GSI Repository (German Federal Government)
Boucenna, S. (2025) · eScholarship@McGill (McGill) · doi:10.82308/39120
Chen, E. (2025) · cIRcle (University of British Columbia) · doi:10.14288/1.0449861
Cárdenas Rivera, G. (2024) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Emerging Trends in Beta Cell Therapy for Type 1 Diabetes Treatments
Lee, J. (2026) · KOBRA Reports · doi:10.64066/kobrareports.25.0018
Editorial: Cellular replacement therapy for diabetes
Sakata, N., Yoshimatsu, G., & Kodama, S. (2026) · Cell Transplantation · doi:10.1177/09636897251392313
Misra, P. S. (2024) · TSpace (University of Toronto)
Haider, R. (2025) · Clinical Orthopaedics and Trauma Care · doi:10.31579/2694-0248/133
Qi, M., Omori, K., Orr, C., Valiente, L., Bilbao, S., Tucker, A., Rawson, J., Gonzalez, N. N., Verret, J., Cuadra, J., et al. (2026) · Transplantation Direct · doi:10.1097/txd.0000000000001930
“2,5,6 A lack of quality pancreata and islets is a barrier to IT access.”
膵島移植におけるアシル化グレリン特異的受容体GHS-R1aアンタゴニストの有効性
Chinen, K. (2022) · Institutional Repositories DataBase (IRDB)
Camille, L. (2018) · theses.fr (ABES) · doi:10.70675/658e9cd6z2fcaz41a8zbeffz90f40fb754f1
Stratégies pour remédier à l'hypoxie dans le pancréas bio-artificiel
Moure, A. G. (2019) · theses.fr (ABES) · doi:10.70675/d4a88d98z2b02z4759zb6eazcb4ecf630341
Pancreatic islet transplantation in patients with diabetes and a kidney transplant
Maanaoui, M. (2023) · theses.fr (ABES) · doi:10.70675/61568379z2dd9z4639z8fe3z5d212aa95b82
Wong, J. M., Dakhili, S. A. T., Kuppan, P., Paramor, J., Cuesta‐Gomez, N., Ussher, J. R., Richard, C., Melling, C. W. J., Nitz, C., Yardley, J. E., et al. (2026) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00007.2025
Gnanasekar, P. (2025) · theses.fr (ABES) · doi:10.70675/1bfa80f3za368z4e5eza1cez31f33e35fe7d
Rao, J. S., Guo, Z., Khashim, Z., Knofczynski, K. R., Tobolt, D. K., Shivakumar, S. B., Rangarajan, P., Herman, A., Abdulla, M., Tran, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720819 · Cited by 1
Self-citationChang, K., Feng, Y., Dong, J., Mou, X., Hao, Y., He, D., Zhang, Y., Feng, X., Lu, X., Chen, Y., et al. (2026) · Food Science and Human Wellness · doi:10.26599/fshw.2026.9251109
Simaeys, D. V., & Berggren, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02934-8
“18,19 Its clinical reach is nonetheless constrained by the scarcity of donor tissue and by the inef fi ciency of engraftment itself.”
Sarvestani, F. S., Yaghobi, R., Maharlooei, M. K., Golshan, M., & Karimi, M. H. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70215
Stage‐Adapted Disease‐Modifying Therapy in Type 1 Diabetes
Ye, C., Jin, Z., & Hu, S. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71210
Tetteh, G. K. (2025) · UWE Research Repository (UWE Bristol)
Regulating cell and xeno-transplants: Learning from medical device oversight
Abbasi, A. B., & Califf, R. M. (2026) · American Journal of Transplantation · doi:10.1016/j.ajt.2026.09.011
Wang, P., Kumar, K., Lambertini, L., Liu, H., Wood, O., CHEN, S., Pillard, A., Scott, D. K., Paulo, J. A., Gygi, S. P., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06857-5
Engineering an Implantable Bioartificial Pancreas to Balance Transport, Containment, and Retrieval
Shi, H., Li, Y., He, C., & Sun, B. (2026) · Artificial Organs · doi:10.1111/aor.70254
Odorico, J. S., Citro, A., de Koning, E. J. P., Kay, T., Latres, E., Millman, J. R., Nostro, M. C., Piemonti, L., Rickels, M. R., Russ, H. A., et al. (2026) · Transplantation · doi:10.1097/tp.0000000000005783
Self-citationLo studio dell'età cellulare sulla funzione delle β cellule derivate da iPSC
Monaco, L. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Chuang, S.-T., Watts, B., Alcazar, O., & Buchwald, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1947013
Chen, L., Hu, X., Zheng, C., Huang, Q., Xu, J., You, X., & Wang, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1981945
“In selected people with recurrent severe hypoglycaemia, it reduces severe events, improves glycaemic stability and may achieve insulin independence (6, 7, 22, 23).”
InfluentialBabaloo, H., Kouchakzade, M. A., & Yazdanian, A. (2026) · The Journal of Applied Tissue Engineering · doi:10.22034/jate.2026.244
Alvarez‐Dominguez, J. R., Liu, M., Sawan, C., Soleimanpour, S. A., Liu, C., Naji, A., & Rickels, M. R. (2026) · Transplant International · doi:10.3389/ti.2026.17176
Self-citationImmune Biomarkers of Islet Transplant Rejection Revealed by Synthetic Immunological Niche
Roy, J., Nejma, A. J., Tarique, M., Talekar, A., Wu, S., Ha, B., Jiang, Y., Yolcu, E. S., & Shea, L. D. (2026) · Advanced Science · doi:10.1002/advs.78154
“However, clinical outcomes are still highly heterogeneous, with only 37.5% of recipients achieving insulin independence at 1 year, 57%–77% maintaining HbA1c 7% long-term, and 69%–84% retaining graft function during 3–8 years of follow-up [ 9–11 ].”
InfluentialCitro, A., & Piemonti, L. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1943061
Shahrestani, S., Todd, R., Khaim, R., Wadhera, V., Tedla, F. M., Holzner, M. L., Shapiro, R., Florman, S. S., & McCune, K. R. (2026) · Diabetology · doi:10.3390/diabetology7100203
Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01)
Korsgren, O., Tufveson, G., Tibell, A., Foss, A., Salmela, K., Sørensen, S. S., Felldin, M., & Andersson, H. (2019) · ImmPort · doi:10.21430/m3yzy4pxcs
Self-citationMarkmann, J., Oberholzer, J., Turgeon, N., Naji, A., Posselt, A., Ricordi, C., Shapiro, J., Kaufman, D., Hering, B., & Luo, X. (2020) · ImmPort · doi:10.21430/m33gz8ur05
Self-citationRaoux, M., Lablanche, S., Jaffredo, M., Pirog, A., Benhamou, P.-Y., Lebreton, F., Wojtusciszyn, A., Bosco, D., Berney, T., Renaud, S., et al. (2023) · doi:10.3389/ti.2023.11512.s001
Berney, T., Andres, A., Bellin, M. D., de Koning, E. J. P., Johnson, P. R. V., Kay, T. W. H., Lundgren, T., Rickels, M. R., Scholz, H., Stock, P. G., et al. (2022) · doi:10.3389/ti.2022.10507.s001
Self-citationBond, Z., Malik, S., Bashir, A., Stocker, R., Buckingham, J., Speight, J., & Shaw, J. A. M. (2023) · doi:10.3389/ti.2023.11659.s001
Metadata
- Authors
- Hering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., Kaufman, D. B., Korsgren, O., Larsen, C. P., Luo, X., Markmann, J. F., Naji, A., Oberholzer, J., Posselt, A. M., Rickels, M. R., Ricordi, C., Robien, M. A., Senior, P. A., Shapiro, A. M. J., Stock, P. G., Turgeon, N. A., & for the Clinical Islet Transplantation Consortium
- Affiliations
- University of Minnesota (US)
- University of Iowa (US)
- National Institutes of Health (US)
- University of Miami (US)
- University of Wisconsin–Madison (US)
- Uppsala University (SE)
- Emory University (US)
- Northwestern University (US)
- Harvard University (US)
- University of Pennsylvania (US)
- Division of Transplantation, University of Illinois Hospital and Health Sciences System, Chicago, IL
- University of California, San Francisco (US)
- University of Alberta (CA)
- Corresponding author
- Clarke, William R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-04-18
- Volume
- 39
- Issue
- 7
- Pages
- 1230-1240
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC5317236
- OpenAlex
- W2341414956
- Cited by
- 645
- References
- 40
- Citations by year
- 2026: 25 · 2025: 51 · 2024: 47 · 2023: 67 · 2022: 75 · 2021: 88 · 2020: 60 · 2019: 79 · 2018: 73 · 2017: 60 · 2016: 20
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases
- National Institute for Diabetes and Digestive and Kidney Diseases (U01-AI-089317, 1-AI-089316, 1-AI-065191, U01-DK-085531, 5U01-DK-070431-10, U01-DK-070431, U01-DK-070460, U01-AI-065193, U01-DK-070430, U01-AI-065192)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, islet transplantation, severe hypoglycemia, hypoglycemia unawareness, glycemic control, HbA1c, immunosuppression, bleeding complications, glomerular filtration rate, donor-specific antibodies, renal function decline, islet autoimmunity
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Immunosuppression Therapy, Male, Middle Aged, North America, Islets of Langerhans Transplantation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.